{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T01:34:27Z","timestamp":1725327267260},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T00:00:00Z","timestamp":1493424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40265-017-0745-x","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T03:45:58Z","timestamp":1493437558000},"page":"941-950","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria"],"prefix":"10.1007","volume":"77","author":[{"given":"Grace","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Standing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bielicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,29]]},"reference":[{"issue":"2","key":"745_CR1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321\u201347.","journal-title":"Clin Microbiol Rev"},{"key":"745_CR2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","volume":"387","author":"R Laxminarayan","year":"2016","unstructured":"Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168\u201375.","journal-title":"Lancet"},{"issue":"11","key":"745_CR3","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1016\/S2214-109X(15)00204-1","volume":"3","author":"AC Seale","year":"2015","unstructured":"Seale AC, Head MG, Fitchett EJA, et al. Neonatal infection: a major burden with minimal funding. Lancet Glob Health. 2015;3(11):e669\u201380.","journal-title":"Lancet Glob Health."},{"key":"745_CR4","doi-asserted-by":"crossref","unstructured":"Synnes A, Luu TM, Moddemann D, On behalf of the Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network, et al. Determinants of developmental outcomes in a very preterm Canadian cohort. Arch Dis Child Fetal Neonatal Ed. 2017;102:F234\u20135.","DOI":"10.1136\/archdischild-2016-311228"},{"key":"745_CR5","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1136\/archdischild-2014-306213","volume":"100","author":"Y Dong","year":"2015","unstructured":"Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch Dis Child Fetal Neonatal Ed. 2015;100:F257\u201363.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"745_CR6","doi-asserted-by":"crossref","first-page":"F350","DOI":"10.1136\/archdischild-2014-306193","volume":"100","author":"ARB Russell","year":"2015","unstructured":"Russell ARB, Kumar R. Early onset neonatal sepsis: diagnostic dilemmas and practical management. Arch Dis Child Fetal Neonatal Ed. 2015;100:F350\u20134.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"745_CR7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1542\/peds.2010-2217","volume":"127","author":"ABJ Stoll","year":"2011","unstructured":"Stoll ABJ, Hansen NI, Watterberg KL, et al. Early onset neonatal sepsis : the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817\u201326.","journal-title":"Pediatrics"},{"issue":"1","key":"745_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/INF.0b013e3182a72ee0","volume":"33","author":"M Tsai","year":"2014","unstructured":"Tsai M, Hsu J, Chu S, et al. Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis. Paediatr Infect Dis J. 2014;33(1):7\u201313.","journal-title":"Paediatr Infect Dis J."},{"issue":"2","key":"745_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pedneo.2014.07.007","volume":"56","author":"L Tsai","year":"2015","unstructured":"Tsai L, Chen Y, Tsou K. The impact of small-for-gestational-age on neonatal outcome among very-low-birth-weight infants. Pediatr Neonatol. 2015;56(2):101\u20137.","journal-title":"Pediatr Neonatol."},{"issue":"1","key":"745_CR10","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1136\/adc.2009.178798","volume":"96","author":"S Vergnano","year":"2011","unstructured":"Vergnano S, Menson E, Kennea N, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F9\u201314.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"745_CR11","unstructured":"Pocket book of hospital care for children. Geneva: World Health Organisation; 2005. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/43206\/1\/9241546700.pdf . Accessed 7 Apr 2017."},{"issue":"1","key":"745_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1745-6215-12-215","volume":"12","author":"I Lutsar","year":"2011","unstructured":"Lutsar I, Trafojer UMT, Heath PT, et al. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials. 2011;12(1):215.","journal-title":"Trials."},{"issue":"7","key":"745_CR13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0b013e31828be70b","volume":"32","author":"CP Hornik","year":"2013","unstructured":"Hornik CP, Herring AH, Benjamin DK, et al. Adverse events associated with meropenem versus imipenem\/ cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J. 2013;32(7):748\u201353.","journal-title":"Pediatr Infect Dis J."},{"issue":"11","key":"745_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.earlhumdev.2015.08.012","volume":"91","author":"B Cailes","year":"2015","unstructured":"Cailes B, Vergnano S, Kortsalioudaki C, et al. The current and future roles of neonatal infection surveillance programmes in combating antimicrobial resistance. Early Hum Dev. 2015;91(11):613\u20138.","journal-title":"Early Hum Dev."},{"issue":"2","key":"745_CR15","doi-asserted-by":"crossref","first-page":"F141","DOI":"10.1136\/adc.2007.120709","volume":"97","author":"AB Russell","year":"2012","unstructured":"Russell AB, Sharland M, Heath PT. Improving antibiotic prescribing in neonatal units: time to act. Arch Dis Child Fetal Neonatal Ed. 2012;97(2):F141\u20136.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"745_CR16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/INF.0b013e3182875227","volume":"32","author":"A Simon","year":"2013","unstructured":"Simon A, Tenenbaum T. Surveillance of multidrug-resistant Gram-negative pathogens in high-risk neonates\u2014does it make a difference? Pediatr Infect Dis J. 2013;32(4):407\u20139.","journal-title":"Pediatr Infect Dis J."},{"issue":"9","key":"745_CR17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/INF.0000000000000339","volume":"33","author":"L Folgori","year":"2014","unstructured":"Folgori L, Livadiotti S, Carletti M, et al. Epidemiology and clinical outcomes of multidrug-resistant, Gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period. Pediatr Infect Dis J. 2014;33(9):929\u201332.","journal-title":"Pediatr Infect Dis J."},{"issue":"7","key":"745_CR18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/INF.0000000000000652","volume":"34","author":"JA Bielicki","year":"2015","unstructured":"Bielicki JA, Lundin R, Sharland M, et al. Antibiotic resistance prevalence in routine bloodstream isolates from children\u2019s hospitals varies substantially from adult surveillance data in Europe. Pediatr Infect Dis J. 2015;34(7):734\u201341.","journal-title":"Pediatr Infect Dis J."},{"issue":"10014","key":"745_CR19","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/S0140-6736(15)00668-6","volume":"387","author":"N Abdula","year":"2016","unstructured":"Abdula N, Macharia J, Motsoaledi A, et al. National action for global gains in antimicrobial resistance. Lancet. 2016;387(10014):e3\u20135.","journal-title":"Lancet"},{"issue":"2","key":"745_CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/archdischild-2012-302033","volume":"98","author":"L Downie","year":"2013","unstructured":"Downie L, Armiento R, Subhi R, et al. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO\u2019s currently recommended antibiotics\u2014systematic review and meta-analysis. Arch Dis Child. 2013;98(2):146\u201354.","journal-title":"Arch Dis Child"},{"issue":"1","key":"745_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jpids\/piu014","volume":"4","author":"K Doare Le","year":"2015","unstructured":"Le Doare K, Bielicki J, Heath PT, et al. Systematic review of antibiotic resistance rates among Gram-negative bacteria in children with sepsis in resource-limited countries. J Pediatr Infect Dis Soc. 2015;4(1):11\u201320.","journal-title":"J Pediatr Infect Dis Soc."},{"issue":"10","key":"745_CR22","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1016\/S2214-109X(16)30148-6","volume":"4","author":"Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration","year":"2016","unstructured":"Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016;4(10):e752\u201360.","journal-title":"Lancet Glob Health."},{"key":"745_CR23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.166.3901.122","volume":"166","author":"D Hendlin","year":"1969","unstructured":"Hendlin D, Stapley EO, Jackson M, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166:122\u20133.","journal-title":"Science"},{"issue":"2","key":"745_CR24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics2020217","volume":"16","author":"A Casta\u00f1eda-Garc\u00eda","year":"2013","unstructured":"Casta\u00f1eda-Garc\u00eda A, Bl\u00e1zquez J, Rodr\u00edguez-Rojas A. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics. 2013;16(2):217\u201336.","journal-title":"Antibiotics."},{"key":"745_CR25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","volume":"235","author":"FM Kahan","year":"1974","unstructured":"Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364\u201386.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"745_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2009.11.011","volume":"35","author":"S Takahata","year":"2010","unstructured":"Takahata S, Ida T, Hiraishi T, et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents. 2010;35(4):333\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"745_CR27","first-page":"1","volume":"12","author":"XL Cao","year":"2016","unstructured":"Cao XL, Shen H, Xu YY, et al. High prevalence of fosfomycinresistancegene fosA3 in bla CTX-M-harbouring Escherichia coli from urine in a Chinese tertiary hospital during 2010\u20132014. Epidemiol Infect. 2016;12:1\u20137.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"745_CR28","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1128\/AAC.00223-13","volume":"57","author":"H Engel","year":"2013","unstructured":"Engel H, Guti\u00e9rrez-Fern\u00e1ndez J, Fl\u00fcckiger C, et al. Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on the murA1 gene. Antimicrob Agents Chemother. 2013;57(6):2801\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"745_CR29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000222051","volume":"23","author":"MA Molina","year":"1977","unstructured":"Molina MA, Olay T, Quero J. Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period. Chemotherapy. 1977;23:217\u201322.","journal-title":"Chemotherapy"},{"issue":"4","key":"745_CR30","first-page":"429","volume":"13","author":"JP Guggenbichler","year":"1978","unstructured":"Guggenbichler JP, Kienel G. Fosfomycin, a new antibiotic drug. Pediatr Padol. 1978;13(4):429\u201336.","journal-title":"Pediatr Padol."},{"issue":"5","key":"745_CR31","first-page":"750","volume":"35","author":"M Guibert","year":"1987","unstructured":"Guibert M, Magny JF, Poudenx F, et al. Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration. Pathol Biol. 1987;35(5):750\u20132.","journal-title":"Pathol Biol."},{"issue":"7","key":"745_CR32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1248\/yakushi.129.829","volume":"129","author":"S Suzuki","year":"2009","unstructured":"Suzuki S, Murayama Y, Sugiyama E, et al. Dose estimation for renal-excretion drugs in neonates and infants based on physiological development of renal function. Yakugaku Zasshi. 2009;129(7):829\u201342.","journal-title":"Yakugaku Zasshi"},{"key":"745_CR33","unstructured":"Iwai N, Nakamura H, Miyazu M, et al. A study of the absorption and excretion of fosfomycin sodium in children [in Japanese]. Jpn J Antibiot. 1991;44(3):345\u201356."},{"issue":"1","key":"745_CR34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","volume":"24","author":"MM Rhodin","year":"2009","unstructured":"Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67\u201376.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"745_CR35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jac\/12.4.357","volume":"12","author":"JM Andrews","year":"1983","unstructured":"Andrews JM, Baquero F, Beltran JM, et al. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother. 1983;12(4):357\u201361.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"745_CR36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","volume":"53","author":"B Pfausler","year":"2004","unstructured":"Pfausler B, Spiss H, Dittrich P, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004;53(5):848\u201352.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"745_CR37","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1128\/AAC.49.11.4448-4454.2005","volume":"49","author":"R Sauermann","year":"2005","unstructured":"Sauermann R, Karch R, Langenberger H, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005;49(11):4448\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"745_CR38","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ijantimicag.2006.05.019","volume":"28","author":"T Mazzei","year":"2006","unstructured":"Mazzei T, Cassetta MI, Fallani S, et al. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28(Suppl 1):S35\u201341.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"745_CR39","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00752-15","volume":"59","author":"F Docobo-P\u00e9rez","year":"2015","unstructured":"Docobo-P\u00e9rez F, Drusano GL, Johnson A, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"745_CR40","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/BF01643430","volume":"18","author":"T Bergan","year":"1990","unstructured":"Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection. 1990;18:S65\u20139.","journal-title":"Infection"},{"issue":"8","key":"745_CR41","first-page":"411","volume":"27","author":"M Borgia","year":"1989","unstructured":"Borgia M, Longo A, Lodola E. Relative bioavailability of fosfomycin and of trometamol after administration of single dose by oral route of fosfomycin trometamol in fasting conditions and after a meal. Int J Clin Pharmacol Ther Toxicol. 1989;27(8):411\u20137.","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"issue":"3","key":"745_CR42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jcf.2006.08.003","volume":"6","author":"M Cree","year":"2007","unstructured":"Cree M, Stacey S, Graham N, et al. Fosfomycin-investigation of a possible new route of administration of an old drug. A case study. J Cyst Fibros. 2007;6(3):244\u20136.","journal-title":"J Cyst Fibros."},{"issue":"S1","key":"745_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000222046","volume":"23","author":"J Llorens","year":"1977","unstructured":"Llorens J, Lobato A, Olay T. The passage of fosfomycin into the cerebrospinal fluid in children\u2019s meningitis. Chemotherapy. 1977;23(S1):189\u201395.","journal-title":"Chemotherapy"},{"issue":"8","key":"745_CR44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11592670-000000000-00000","volume":"50","author":"F Traunm\u00fcller","year":"2011","unstructured":"Traunm\u00fcller F, Popovic M, Konz KH, et al. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Clin Pharmacokinet. 2011;50(8):493\u2013503.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"745_CR45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","volume":"51","author":"RFW Cock De","year":"2012","unstructured":"De Cock RFW, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105\u201317.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"745_CR46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","volume":"4","author":"D Iarikov","year":"2015","unstructured":"Iarikov D, Wassel R, Farley J, et al. Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther. 2015;4(4):433\u201358.","journal-title":"Infect Dis Ther."},{"issue":"1","key":"745_CR47","doi-asserted-by":"crossref","first-page":"F56","DOI":"10.1136\/fn.83.1.F56","volume":"83","author":"G Hartnoll","year":"2000","unstructured":"Hartnoll G, B\u00e9tr\u00e9mieux P, Modi N. Body water content of extremely preterm infants at birth. Arch Dis Child Fetal Neonatal Ed. 2000;83(1):F56\u20139.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"745_CR48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/pan.12326","volume":"24","author":"F O\u2019Brien","year":"2014","unstructured":"O\u2019Brien F, Walker IA. Fluid homeostasis in the neonate. Paediatr Anaesth. 2014;24(1):49\u201359.","journal-title":"Paediatr Anaesth"},{"key":"745_CR49","doi-asserted-by":"crossref","unstructured":"Taylor CG, Mascar\u00f3s E, Rom\u00e1n J, et al. Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin. Chemotherapy. 1977;23(1):310\u20134.","DOI":"10.1159\/000222068"},{"issue":"5","key":"745_CR50","first-page":"437","volume":"31","author":"S Rossignol","year":"1984","unstructured":"Rossignol S, Regnier C. Fosfomycin in severe infection in neonatology. Ann Pediatr. 1984;31(5):437\u201344.","journal-title":"Ann Pediatr."},{"issue":"1","key":"745_CR51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.idcr.2014.11.004","volume":"2","author":"S Algubaisi","year":"2015","unstructured":"Algubaisi S, Buhrer C, Thomale UW, et al. Favorable outcome in cerebral abscesses caused by Citrobacter koseri in a newborn infant. IDCases. 2015;2(1):22\u20134.","journal-title":"IDCases."},{"issue":"10","key":"745_CR52","first-page":"681","volume":"36","author":"B Guillois","year":"1989","unstructured":"Guillois B, Guillemin MG, Thoma M, et al. Neonatal pleuropulmonary staphylococcal infection with multiple abscesses of the liver. Ann Pediatr. 1989;36(10):681\u20134.","journal-title":"Ann Pediatr."},{"issue":"1","key":"745_CR53","first-page":"21","volume":"37","author":"JB Gouyon","year":"1990","unstructured":"Gouyon JB, Fran\u00e7ois C, Semama D, et al. Nosocomial Staphylococcus epidermidis and Staphylococcus aureus septicemias in neonates. Ann Pediatr. 1990;37(1):21\u20135.","journal-title":"Ann Pediatr."},{"issue":"4","key":"745_CR54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2008.10.008","volume":"33","author":"N Hepping","year":"2009","unstructured":"Hepping N, Simon A. Fosfomycin in paediatric cancer patients: a feasible alternative to glycopeptides? Int J Antimicrob Agents. 2009;33(4):389.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"745_CR55","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069\u201377.","journal-title":"Clin Infect Dis"},{"key":"745_CR56","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732\u20139.","journal-title":"Int J Infect Dis."},{"issue":"4","key":"745_CR57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","volume":"47","author":"KZ Vardakas","year":"2016","unstructured":"Vardakas KZ, Legakis NJ, Triarides N, et al. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269\u201385.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"745_CR58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/ja.2010.105","volume":"63","author":"X Yu","year":"2010","unstructured":"Yu X, Song X, Cai Y, et al. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot. 2010;63(11):657\u20139.","journal-title":"J Antibiot"},{"issue":"9","key":"745_CR59","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","volume":"55","author":"C Lu","year":"2011","unstructured":"Lu C, Liu C, Huang Y, et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 2011;55(9):4295\u2013301.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"745_CR60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0974-7796.148585","volume":"7","author":"A Sultan","year":"2015","unstructured":"Sultan A, Rizvi M, Khan F, et al. Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? Urol Ann. 2015;7(1):26\u201330.","journal-title":"Urol Ann."},{"key":"745_CR61","doi-asserted-by":"crossref","unstructured":"Chiquet C, Maurin M, Altayrac J, et al. Correlation between clinical data and antibiotic resistance in coagulase-negative Staphylococcus species isolated from 68 patients with acute post-cataract endophthalmitis. Clin Microbiol Infect. 2015;21(6):592.e1\u20138.","DOI":"10.1016\/j.cmi.2015.01.028"},{"issue":"5","key":"745_CR62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijantimicag.2010.01.010","volume":"35","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(5):497\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"745_CR63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1157\/13059822","volume":"22","author":"JJ Gonz\u00e1lez","year":"2004","unstructured":"Gonz\u00e1lez JJ, Andreu A, Grupo de Estudio de Infecci\u00f3n Perinatal, Sociedad Espanola de Enfermedades Infecciosas y MicrobiologiaClinica. Susceptibility of vertically transmitted Group B streptococci to antimicrobial agents [in Spanish]. Enferm Infecc Microbiol Clin. 2004;22(5):286\u201391.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"1","key":"745_CR64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12879-016-1888-1","volume":"16","author":"PC Matthews","year":"2016","unstructured":"Matthews PC, Barrett LK, Warren S, et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis. 2016;16(1):556.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"745_CR65","doi-asserted-by":"crossref","first-page":"245","DOI":"10.47102\/annals-acadmedsg.V45N6p245","volume":"45","author":"YT Chen","year":"2016","unstructured":"Chen YT, Ahmad Murad K, Ng LS, et al. In vitro efficacy of six alternative antibiotics against multidrug resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections. Ann Acad Med Singapore. 2016;45(6):245\u201350.","journal-title":"Ann Acad Med Singapore"},{"issue":"11","key":"745_CR66","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1128\/AAC.01345-16","volume":"60","author":"A Ranjan","year":"2016","unstructured":"Ranjan A, Shaik S, Mondal A, et al. Molecular epidemiology and genome dynamics of New Delhi metallo-\u03b2-lactamase-producing extraintestinal pathogenic Escherichia coli strains from India. Antimicrob Agents Chemother. 2016;60(11):6795\u2013805.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"745_CR67","doi-asserted-by":"crossref","first-page":"67580","DOI":"10.2217\/fmb.13.31","volume":"8","author":"RD Sahni","year":"2013","unstructured":"Sahni RD, Balaji V, Varghese R, et al. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiol. 2013;8(5):67580.","journal-title":"Future Microbiol."},{"issue":"3","key":"745_CR68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jmii.2012.05.005","volume":"46","author":"A Cheng","year":"2013","unstructured":"Cheng A, Liu C, Tsai H, et al. Bacteremia caused by Pantoea agglomerans at a medical center in Taiwan, 2000\u20132010. J Microbiol Immunol Infect. 2013;46(3):187\u201394.","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"745_CR69","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2013.56","volume":"66","author":"JM Pogue","year":"2013","unstructured":"Pogue JM, Marchaim D, Abreu-Lanfranco O, et al. Fosfomycinactivity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008\u201310. J Antibiot. 2013;66(10):625\u20137.","journal-title":"J Antibiot"},{"issue":"9","key":"745_CR70","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/AAC.00355-16","volume":"60","author":"B Vanscoy","year":"2016","unstructured":"Vanscoy B, Mccauley J, Bhavnani SM, et al. Relationship between fosfomycin exposure and amplification of Escherichia coli subpopulations with reduced susceptibility in a hollow-fiber infection model. Antimicrob Agents Chemother. 2016;60(9):5141\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"745_CR71","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/AAC.47.9.2850-2858.2003","volume":"47","author":"AI Nilsson","year":"2003","unstructured":"Nilsson AI, Berg OG, Aspevall O, et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003;47(9):2850\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"745_CR72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","volume":"67","author":"DE Karageorgopoulos","year":"2012","unstructured":"Karageorgopoulos DE, Wang R, Yu XH, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J Antimicrob Chemother. 2012;67(2):255\u201368.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"745_CR73","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dkq346","volume":"65","author":"N Lara","year":"2010","unstructured":"Lara N, Cuevas O, Arroyo M, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010;65(11):2459\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"745_CR74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ijantimicag.2015.07.021","volume":"46","author":"I Rodr\u00edguez-Avial","year":"2015","unstructured":"Rodr\u00edguez-Avial I, Pena I, Picazo JJ, et al. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46(6):616\u201321.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"745_CR75","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/jac\/dkw115","volume":"71","author":"CC Walsh","year":"2016","unstructured":"Walsh CC, Landersdorfer CB, McIntosh MP, et al. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother. 2016;71(8):2218\u201329.","journal-title":"J Antimicrob Chemother"},{"key":"745_CR76","doi-asserted-by":"crossref","unstructured":"Sime FB, Johnson A, Whalley S, et al. Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy. Antimicrob Agents Chemother. 2016;61(1):pii: e01763\u201316.","DOI":"10.1128\/AAC.01763-16"},{"issue":"9208","key":"745_CR77","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(00)90015-1","volume":"355","author":"P Man De","year":"2000","unstructured":"De Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355(9208):973\u20138.","journal-title":"Lancet"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0745-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:54:51Z","timestamp":1658973291000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0745-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,29]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0745-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,29]]}}}